Passage BIO (PASG) Assets Average (2020 - 2026)
Passage BIO (PASG) posted quarterly Assets Average of $49.4 million for Q1 2026, down 47.59% year-over-year from $94.2 million in Q1 2025, and down 27.63% quarter-over-quarter from $68.2 million in Q4 2025.
Passage BIO (PASG) Assets Average (2020 - 2026) Analysis & Trends
Passage BIO's Assets Average history runs 7 years deep, the most recent figure standing at $49.4 million for Q1 2026.
- In Q1 2026, Assets Average fell 47.59% year-over-year to $49.4 million; the TTM figure through Mar 2026 stood at $49.4 million (down 47.59% YoY), while the FY2025 annual figure was $82.3 million, down 34.89% from the prior year.
- Assets Average for Q1 2026 stood at $49.4 million, down from $68.2 million in the prior quarter.
- The five-year high for Assets Average was $344.2 million in Q1 2022, with the low at $49.4 million in Q1 2026.
- The 5-year median for Assets Average is $145.5 million (2024), against an average of $167.7 million.
- The sharpest annual moves came in 2022 and 2026: Assets Average retreated 13.22% in 2022, then sank 47.59% in 2026.
- Passage BIO's Assets Average stood at $256.8 million in 2022, then sank by 37.73% to $159.9 million in 2023, then tumbled by 33.03% to $107.1 million in 2024, then plunged by 36.29% to $68.2 million in 2025, then retreated by 27.63% to $49.4 million in 2026.
- Business Quant data shows PASG's Assets Average at $49.4 million in Q1 2026, $68.2 million in Q4 2025, and $76.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | 30.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.82 Mn |
| Mar 31, 2026 | 49.37 Mn |
| Dec 31, 2025 | 68.22 Mn |
| Sep 30, 2025 | 76.68 Mn |
| Jun 30, 2025 | 82.60 Mn |
| Mar 31, 2025 | 94.21 Mn |
| Dec 31, 2024 | 107.08 Mn |
| Sep 30, 2024 | 118.57 Mn |
| Jun 30, 2024 | 132.96 Mn |
| Mar 31, 2024 | 145.54 Mn |
| Dec 31, 2023 | 159.90 Mn |
| Sep 30, 2023 | 181.48 Mn |
| Jun 30, 2023 | 203.47 Mn |
| Mar 31, 2023 | 228.40 Mn |
| Dec 31, 2022 | 256.80 Mn |
| Sep 30, 2022 | 284.73 Mn |
| Jun 30, 2022 | 316.32 Mn |
| Mar 31, 2022 | 344.15 Mn |
| Dec 31, 2021 | 373.01 Mn |
| Sep 30, 2021 | 415.23 Mn |